首批400例Conserve Plus髋关节表面置换术20年结果
本研究报道了单中心连续400例金属对金属髋关节表面置换术(HRA)的20年以上临床结果。355例患者(400髋)平均随访16.5年,20年以任何指征翻修为终点的Kaplan-Meier生存率为83.5%。发育性髋关节发育不良(HR 2.199,95%CI 1.140-4.239,p=0.019)和低BMI(HR 0.931,95%CI 0.873-0.994,p=0.032)是翻修的危险因素。
要点
- 20年生存率83.5%,优于20年前同类年轻患者全髋置换。
- 发育性髋关节发育不良和低BMI是翻修危险因素。
- 女性性别仅因髋关节发育不良和小尺寸假体成为危险因素。
核心结论
- 该初始系列20年生存率83.5%,提示对几乎所有剩余患者器械具有满意的终身耐久性。
主要发现
- 平均随访16.5年(0.1-24.0),34例患者(37髋)死亡。
- UCLA髋关节评分疼痛、行走、功能、活动平均分别为9.3(2-10)、9.1(3-10)、9.0(3-10)、6.9(2-10)。
- SF-12生理成分平均48.4(16.0-62.1),心理成分平均48.5(10.5-66.5),与美国一般人群无差异。
- 55例患者共60髋接受翻修。
- 放射学分析显示除1髋外所有髋均保持固定。
关键数值与推荐
- 以任何指征翻修为终点,Kaplan-Meier 20年生存率为83.5%。
- 发育性髋关节发育不良是翻修危险因素(HR 2.199,95%CI 1.140-4.239,p=0.019)。
- 低BMI是翻修危险因素(HR 0.931,95%CI 0.873-0.994,p=0.032)。
- 无与翻修手术相关的金属过敏病例。
临床怎么用
- 在严格选择的年轻患者中,Conserve Plus HRA可提供满意的长期耐久性。
- 对发育性髋关节发育不良或低BMI患者应谨慎评估翻修风险。
局限性
- 单中心回顾性设计,部分患者失访或死亡。
- 未报告金属离子水平或影像学不良局部组织反应的具体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Adverse local tissue reactions associated with abnormal wear considerably slowed down the general use of metal-on-metal (MoM) hip resurfacing arthroplasty (HRA), now limited to a few specialized centres. In this study, we provide the clinical results of 400 consecutive MoM HRAs implanted more than 20 years ago in one such centre. METHODS: A total of 355 patients (400 hips) were treated with Conserve Plus HRA between November 1996 and November 2000. There were 96 female (27%) and 259 male patients (73%). Their mean age was 48.2 years (SD 10.9). The University of California, Los Angeles (UCLA) hip scores and 12-item Short Form Survey (SF-12) quality of life scores were reported. Survivorship was assessed using Kaplan-Meier analyses. RESULTS: The mean follow-up was 16.5 years (0.1 to 24.0), including 34 patients (37 hips) who died. The mean UCLA hip scores were 9.3 (2 to 10), 9.1 (3 to 10), 9.0 (3 to 10), and 6.9 (2 to 10) for pain, walking, function, and activity, respectively. The mean SF-12 scores were 48.4 (16.0 to 62.1) for the physical component and 48.5 (10.5 to 66.5) for the mental component, and did not differ from those of the general population of the USA. A total of 60 hips in 55 patients were revised. Using revision for any indication as the endpoint, the Kaplan-Meier survivorship was 83.5% at 20 years. A diagnosis of developmental dysplasia (hazard ratio (HR) 2.199 (95% confidence interval (CI) 1.140 to 4.239); p = 0.019) and a low BMI (HR 0.931 (95% CI 0.873 to 0.994); p = 0.032) were risk factors for revision. Female sex was a risk factor only because of hip dysplasia and small component size. There were no cases of metal sensitivity associated with revision surgery. Radiological analysis showed persistent fixation in all but one hip. CONCLUSION: The 83.5% 20-year survivorship of this initial series surpasses that of total hip arthroplasties in use 20 years ago in these young patients, suggesting satisfactory lifelong durability of the device for almost all of the remaining patients. Cite this article: Bone Joint J 2021;103-B(7 Supple B):25-32.
引用
- Amstutz HC, Le Duff MJ. The 20-year results of the first 400 Conserve Plus hip resurfacing arthroplasties. Bone Joint J. 2021. PMID: 34192905. doi:10.1302/0301-620X.103B7.BJJ-2020-2256.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。